Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03280264 · OUTCOME

The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase.

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism · Source last updated 2021-05-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 24 weeks

Groups in this outcome

KHK7580 (2-24 mg)

KHK7580 was orally administered daily for up to week 52.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
KHK7580 (2-24 mg)18

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
KHK7580 (2-24 mg)14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        14
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
groups
  1. description
    KHK7580 was orally administered daily for up to week 52.
    id
    OG000
    title
    KHK7580 (2-24 mg)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 24 weeks
title
The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase.
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice